EA201592183A1 - Ингибиторы bace - Google Patents

Ингибиторы bace

Info

Publication number
EA201592183A1
EA201592183A1 EA201592183A EA201592183A EA201592183A1 EA 201592183 A1 EA201592183 A1 EA 201592183A1 EA 201592183 A EA201592183 A EA 201592183A EA 201592183 A EA201592183 A EA 201592183A EA 201592183 A1 EA201592183 A1 EA 201592183A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bace inhibitors
bace
inhibitors
compound
pharmaceutically acceptable
Prior art date
Application number
EA201592183A
Other languages
English (en)
Other versions
EA027880B1 (ru
Inventor
Стивен Джеймс Грин
Эрик Джеймс Хембр
Дастин Джеймс Мерготт
Юань Ши
Брайан Морган Уотсон
Леонард Ларри Виннероски Дж.
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201592183A1 publication Critical patent/EA201592183A1/ru
Publication of EA027880B1 publication Critical patent/EA027880B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

В настоящем изобретении предложено соединение формулы IIIгде А представляет собойи Z, R, R, Rи Rявляются такими, как определено в настоящем описании, или его фармацевтически приемлемая соль.
EA201592183A 2013-06-18 2014-06-11 Ингибиторы bace EA027880B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836175P 2013-06-18 2013-06-18
US201361877373P 2013-09-13 2013-09-13
PCT/US2014/041825 WO2014204730A1 (en) 2013-06-18 2014-06-11 Bace inhibitors

Publications (2)

Publication Number Publication Date
EA201592183A1 true EA201592183A1 (ru) 2016-05-31
EA027880B1 EA027880B1 (ru) 2017-09-29

Family

ID=51059662

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592183A EA027880B1 (ru) 2013-06-18 2014-06-11 Ингибиторы bace

Country Status (14)

Country Link
US (2) US9029367B2 (ru)
EP (1) EP3010925B1 (ru)
JP (1) JP2016522254A (ru)
KR (1) KR101780140B1 (ru)
CN (1) CN105324385A (ru)
AU (1) AU2014281032B2 (ru)
BR (1) BR112015029348A8 (ru)
CA (1) CA2910415C (ru)
EA (1) EA027880B1 (ru)
ES (1) ES2657905T3 (ru)
JO (1) JO3318B1 (ru)
MX (1) MX2015017156A (ru)
TW (1) TWI639607B (ru)
WO (1) WO2014204730A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
AR103680A1 (es) * 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
MX2018001699A (es) 2015-08-12 2018-05-07 H Lundbeck As 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1.
US20180230160A1 (en) * 2015-08-12 2018-08-16 H. Lundbeck A/S 2-amino-7a-phenyl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines as bace1 inhibitors
TWI675034B (zh) * 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
JP6889466B2 (ja) * 2016-12-09 2021-06-18 学校法人 名城大学 アミド基を含む単離された化合物の塩、その製造方法及びこれを用いたアミド化合物の合成方法
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
CN111217709A (zh) * 2018-11-27 2020-06-02 南京药石科技股份有限公司 一种（1-氟环丙基）甲胺盐酸盐的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201004961A (en) 2005-06-14 2010-02-01 Schering Corp Aspartyl protease inhibitors
CN101346357B (zh) 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
BRPI0811034A2 (pt) 2007-04-24 2014-12-09 Shionogi & Co Derivados de aminodi-hidrotiazina substituídos com um grupo cíclico e seus usos e composições farmacêuticas
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PE20091438A1 (es) * 2008-01-18 2009-09-26 Eisai Randd Man Co Ltd Derivados fusionados de aminodihidrotiazina
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
CA2727859C (en) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
CA2738150A1 (en) 2008-09-30 2010-04-08 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
JPWO2011070781A1 (ja) 2009-12-09 2013-04-22 塩野義製薬株式会社 置換アミノチアジン誘導体
UA103272C2 (ru) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-амино-5,5-дифтор-5,6-дигидро-4h-оксазины как ингибиторы bace1 и/или bace2
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
EP2511269A4 (en) * 2009-12-11 2013-04-24 Shionogi & Co FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
CA2814014A1 (en) 2011-01-21 2012-07-26 Branko MITASEV Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
AR086539A1 (es) 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
MX2013014007A (es) 2011-06-07 2014-03-12 Hoffmann La Roche [1,3] oxazinas.
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
MY168412A (en) 2011-11-25 2018-11-09 Adverio Pharma Gmbh Method for producing substituted 5-fluoro-1h-pyrazolopyridines
CN104245680B (zh) 2012-04-27 2016-11-23 卫材R&D管理有限公司 用于生产5-(二氟甲基)吡嗪-2-甲酸的方法及其生产中间体
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds

Also Published As

Publication number Publication date
US9169271B2 (en) 2015-10-27
EA027880B1 (ru) 2017-09-29
US9029367B2 (en) 2015-05-12
AU2014281032A1 (en) 2015-11-12
AU2014281032B2 (en) 2016-09-29
EP3010925A1 (en) 2016-04-27
TW201536793A (zh) 2015-10-01
JP2016522254A (ja) 2016-07-28
BR112015029348A8 (pt) 2020-03-17
TWI639607B (zh) 2018-11-01
CA2910415A1 (en) 2014-12-24
JO3318B1 (ar) 2019-03-13
KR101780140B1 (ko) 2017-09-19
MX2015017156A (es) 2016-03-16
CA2910415C (en) 2017-09-05
BR112015029348A2 (pt) 2017-07-25
US20150210716A1 (en) 2015-07-30
KR20160009052A (ko) 2016-01-25
CN105324385A (zh) 2016-02-10
ES2657905T3 (es) 2018-03-07
EP3010925B1 (en) 2017-10-04
WO2014204730A1 (en) 2014-12-24
US20140371212A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
EA201591491A1 (ru) Соединения тетрагидропирролотиазина
EA201592183A1 (ru) Ингибиторы bace
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
EA201792039A1 (ru) Гетероциклические амины в качестве ингибиторов киназы
EA201792021A1 (ru) Ингибитор jak
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201691085A1 (ru) Замещенные бензамиды и способы их применения
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201791684A1 (ru) Селективные ингибиторы bace1
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
EA201590321A1 (ru) Дейтерированный барицитиниб
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
RS54730B1 (sr) Inhibitori beta sekretaze
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201690894A1 (ru) Феноксиэтилы
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201500931A1 (ru) Производные пиридин-4-ила
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU